ZA862356B - Vaccinia dna - Google Patents

Vaccinia dna

Info

Publication number
ZA862356B
ZA862356B ZA862356A ZA862356A ZA862356B ZA 862356 B ZA862356 B ZA 862356B ZA 862356 A ZA862356 A ZA 862356A ZA 862356 A ZA862356 A ZA 862356A ZA 862356 B ZA862356 B ZA 862356B
Authority
ZA
South Africa
Prior art keywords
vaccinia dna
vaccinia
dna
Prior art date
Application number
ZA862356A
Other languages
English (en)
Inventor
Hendrik Gerard Stunnenberg
Riccardo Wittek
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA862356B publication Critical patent/ZA862356B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
ZA862356A 1985-04-04 1986-03-27 Vaccinia dna ZA862356B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858508845A GB8508845D0 (en) 1985-04-04 1985-04-04 Vaccinia dna

Publications (1)

Publication Number Publication Date
ZA862356B true ZA862356B (en) 1986-11-26

Family

ID=10577216

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA862356A ZA862356B (en) 1985-04-04 1986-03-27 Vaccinia dna

Country Status (9)

Country Link
US (1) US5017487A (de)
EP (1) EP0198328B1 (de)
JP (2) JPS61289888A (de)
AU (1) AU595190B2 (de)
CA (1) CA1316849C (de)
DE (1) DE3685833T2 (de)
DK (1) DK112586A (de)
GB (1) GB8508845D0 (de)
ZA (1) ZA862356B (de)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82104A0 (en) * 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US5348741A (en) * 1987-02-03 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Vector for recombinant poxvirus expressing rabies virus glycoprotein
US5578468A (en) * 1987-08-10 1996-11-26 Duke University Site-specific RNA cleavage
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5691170A (en) * 1989-04-18 1997-11-25 Therion Biologics Generation of hybrid genes and proteins by virus-mediated recombination
DK0437604T3 (da) * 1989-06-21 2003-09-15 Univ Rockefeller Rekombinant poxvirus- og streptokok M-proteinvaccine
DK0512011T3 (da) * 1990-01-26 1994-05-09 Immuno Ag Blodfaktorer fremstillet ved rekombinant DNA-teknologi, fremgangsmåde til ekspression af blodfaktorerne samt vacciniavirusrekombinanter anvendt ved fremgangsmåden
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
CA2106464A1 (en) * 1991-03-20 1992-09-21 Enzo Paoletti Malaria recombinant poxvirus vaccine
ATE248924T1 (de) * 1991-05-06 2003-09-15 Us Gov Health & Human Serv Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US5736378A (en) * 1991-09-12 1998-04-07 The Scripps Research Institute Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JP3701966B2 (ja) * 1993-01-26 2005-10-05 ウェイナー，デービッド・ビー 遺伝物質送達のための組成物および方法
US6348449B1 (en) 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
DE69535288T2 (de) * 1994-05-13 2007-04-05 Thomas Jefferson University Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
AUPN658795A0 (en) * 1995-11-15 1995-12-07 Commonwealth Scientific And Industrial Research Organisation Method of producing alpha 2, 3 sialyltransferase
AU2800797A (en) 1996-04-05 1997-10-29 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2254082C (en) * 1996-05-03 2012-09-11 Thomas Jefferson University Metastatic colorectal cancer vaccine
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
EP1002103B1 (de) 1997-08-04 2007-10-17 Cell Genesys, Inc. Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US7135333B1 (en) 1997-08-07 2006-11-14 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
EP2386630A1 (de) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidinkinasemutanten und Fusionsproteine mit Thymidinkinase- und Guanylatkinaseaktivität
CA2316397A1 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
KR100743894B1 (ko) 1998-02-27 2007-07-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 백신, 면역치료제 및 그의 이용 방법
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR20010041992A (ko) 1998-03-18 2001-05-25 길리스 스티브 폐암의 치료와 진단을 위한 화합물 및 이를 위한 방법
US6375952B1 (en) 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6194178B1 (en) 1998-09-03 2001-02-27 Synsorb Biotech Inc. Method for the production of sialylated oligosaccharides
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP2042598A1 (de) 1998-11-18 2009-04-01 Oxford Biomedica (UK) Limited Verwendung vom Krebs-assoziierten Antigen 5T4 zur Immuntherapie
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
TR200102500T2 (tr) 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
CA2362873A1 (en) * 1999-03-03 2000-09-08 The Trustees Of The University Of Pennsylvania Vaccines and gene therapy compositions and methods of making and using the same
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) * 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
DE60039353D1 (de) 1999-04-02 2008-08-14 Corixa Corp Verbindungen und verfahren für therapie und diagnose von lungenkrebs
WO2000066162A1 (en) 1999-04-30 2000-11-09 The Trustees Of The University Of Pennsylvania Mutant human cd80 and compositions for and methods of making and using the same
US20030232060A1 (en) * 1999-07-28 2003-12-18 Smith Stephen M. Attenuated, doxycycline-inducible human immunodeficiency virus proviral molecular clones
AU5615601A (en) 2000-02-23 2001-09-03 Smithkline Beecham Biolog Novel compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7575860B2 (en) * 2000-03-07 2009-08-18 Evans David H DNA joining method
ATE469242T1 (de) * 2000-03-27 2010-06-15 Univ Jefferson Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal
EP1278855B1 (de) 2000-04-21 2008-03-12 Corixa Corporation Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
MXPA02011486A (es) 2000-05-19 2004-01-26 Corixa Corp Tratamiento profilactico y terapeutico de enfermedades infecciosas, autoinmunes y alergicas con compuestos a base de mono y disacarido.
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
ATE526994T1 (de) 2000-06-20 2011-10-15 Corixa Corp Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2004525604A (ja) * 2000-07-14 2004-08-26 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア Ｈｉｖアクセサリータンパク質をコードするｄｎａワクチン
US7829276B2 (en) * 2000-09-18 2010-11-09 Thomas Jefferson University Methods of using CRCA-1 as a stomach and esophageal cancer marker
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
WO2002029088A2 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US8216585B2 (en) * 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
DE60335755D1 (de) 2002-07-18 2011-02-24 Univ Washington Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
US20070224124A1 (en) * 2002-09-30 2007-09-27 University Of South Florida Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1589934B1 (de) 2003-01-06 2015-09-23 Corixa Corporation Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung
EP1610816B1 (de) 2003-03-28 2013-01-02 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mva virus, der modifizierte hiv hülle, gag und pol gene exprimiert
AU2004249191B2 (en) 2003-06-13 2011-01-06 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
WO2005007673A2 (en) * 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
JP2007509837A (ja) 2003-08-01 2007-04-19 中国医学科学院基礎医学研究所 多価エピトープキメラ遺伝子ワクチンの製法
US7763592B1 (en) * 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
EP2199801B1 (de) 2004-07-14 2013-05-29 The Regents of The University of California Biomarker zur Früherkennung von Eierstockkrebs
KR101068289B1 (ko) * 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
WO2006020684A2 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
EP1789438B1 (de) 2004-08-27 2015-04-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Rekombinante MVA-Viren die modifizierte HIV Clade A/G, Clade B und Clade C env, gag und pol Gene exprimieren
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP3312272B1 (de) 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation der replikationsrate durch verwendung von seltener verwendeten synonymen kodonen
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
EP1701165A1 (de) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutischer und diagnostischer Gebrauch von TKTL1 sowie seiner Inhibitoren und Aktivatoren
EP2392349A3 (de) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Impfstoffe gegen Chlamydieninfektion
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
KR20120089475A (ko) 2005-04-29 2012-08-10 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
EP2045268B1 (de) 2005-05-13 2011-09-21 Oxford BioMedica (UK) Limited Vom Tumorantigen 5t4 abgeleitete Mhc-Klasse-I- und II-Peptidantigene
BRPI0613770A2 (pt) * 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anticorpos anti-cd26 e métodos de uso destes
CN105012953B (zh) 2005-07-25 2018-06-22 阿普泰沃研发有限责任公司 用cd37-特异性和cd20-特异性结合分子减少b-细胞
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
EP1945247A1 (de) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
DK1976871T3 (da) * 2006-01-13 2011-12-12 Univ Pennsylvania Vacciner og immunterapeutika under anvendelse af codonoptimerede IL-15 og fremgangsmåder til anvendelse deraf
EP1981905B1 (de) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia-impfstoff
JP5524610B2 (ja) 2006-04-07 2014-06-18 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
RU2487888C2 (ru) * 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
KR20230042399A (ko) 2006-07-28 2023-03-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2068918T3 (da) 2006-09-26 2012-07-30 Infectious Disease Res Inst Vaccinesammensætning omfattende syntetisk adjuvant
EP2170384B1 (de) 2007-07-02 2016-04-13 Etubics Corporation Verfahren und zusammensetzungen zur herstellung eines adenovirus-vektors zur verwendung mit multiplen impfungen
CN101990439A (zh) * 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
CN102016023A (zh) 2008-04-04 2011-04-13 宾夕法尼亚州立大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
CN107083391A (zh) * 2008-04-04 2017-08-22 宾夕法尼亚大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
EP3023502A1 (de) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
ATE513856T1 (de) * 2008-04-11 2011-07-15 Emergent Product Dev Seattle Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
WO2010036652A1 (en) * 2008-09-23 2010-04-01 Thomas Jefferson University Cancer vaccines against mucosal antigens and methods of making and using the same
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
JP5753090B2 (ja) 2008-10-29 2015-07-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良型ｈｃｖワクチンおよびその使用方法
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
RU2560182C2 (ru) 2009-06-05 2015-08-20 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
EP2477659A4 (de) 2009-09-14 2014-01-15 Univ Pennsylvania Impfstoffe und immuntherapeutika mit dafür kodierenden il-15-rezeptor-alpha- und/oder nukleinsäuremolekülen sowie verfahren zu ihrer anwendung
WO2011066048A1 (en) 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
KR20210149203A (ko) 2009-11-02 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген
JP6125232B2 (ja) 2010-02-08 2017-05-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｒａｎｔｅｓをコードする核酸分子、ならびにこれを含む組成物およびこれを用いる方法
MX346784B (es) 2010-11-12 2017-03-31 Inovio Pharmaceuticals Inc Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EP2670443A4 (de) 2011-01-31 2015-10-14 Univ Pennsylvania Für nukleinsäuremolekühle kodierende neue herpes-antigene, impfstoffe damit und verwendungsverfahren dafür
JP6153473B2 (ja) 2011-02-11 2017-06-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｂ型肝炎ウイルスコアタンパク質をコードする核酸分子およびそれを含むワクチン
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
WO2012154994A2 (en) 2011-05-10 2012-11-15 The Regents Of The University Of Californa A novel adenovirus isolated from titi monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
AU2012273153A1 (en) 2011-06-21 2013-05-02 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
ES2758713T3 (es) 2011-07-11 2020-05-06 Inovio Pharmaceuticals Inc Vacuna de ADN contra el virus de Lassa
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
WO2013033260A1 (en) 2011-08-29 2013-03-07 The Regents Of The University Of California Use of hdl-related molecules to treat and prevent proinflammatory conditions
CA3161127A1 (en) 2011-10-12 2013-04-18 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
KR101913674B1 (ko) 2011-10-24 2018-10-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법
KR102445129B1 (ko) 2011-12-12 2022-09-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
KR20140116095A (ko) 2011-12-12 2014-10-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Mrsa pbp2a 및 이의 단편들을 포함하는 단백질, 이를 인코딩한 핵산, 및 mrsa 감염을 예방 및 치료하기 위한 조성물 및 그의 용도
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
CN104619719A (zh) 2012-04-10 2015-05-13 宾夕法尼亚大学理事会 人呼吸道合胞病毒共有抗原、由其制备的核酸构建体和疫苗及其使用方法
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
US10232030B2 (en) 2013-03-12 2019-03-19 Inovio Pharmaceuticals, Inc. Vaccines for human papilloma virus and methods for using the same
EP2970410B1 (de) 2013-03-15 2020-01-22 The Regents of The University of California Mitochondrienderiviertes peptid mots3 als regler des stoffwechsels und des überlebens von zellen
CN114045295A (zh) 2013-03-15 2022-02-15 宾夕法尼亚大学理事会 口蹄疫病毒(fmdv)共有蛋白、其编码序列以及由其制造的疫苗
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
EA034110B1 (ru) 2013-03-15 2019-12-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Противораковые вакцины и способы лечения с их применением
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
WO2014172661A1 (en) 2013-04-19 2014-10-23 The Regent Of The University Of California Lone star virus
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
WO2015003003A1 (en) 2013-07-01 2015-01-08 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2015277194B2 (en) 2014-06-17 2020-10-22 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells
JP2017521654A (ja) 2014-06-27 2017-08-03 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ ヒトペギウイルス２（ＨＰｇＶ−２）を検出するための組成物および方法
EP3270897A4 (de) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogene zusammensetzungen zur verwendung als impfstoff gegen bordetella
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3359651A1 (de) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Stamm des menschlichen rota-virus g9p[6] und verwendung als impfstoff
US11278607B2 (en) 2016-01-08 2022-03-22 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
RU2020110148A (ru) 2016-01-19 2020-09-18 Пфайзер Инк. Противораковые вакцины
JP7195148B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｔｌｒアゴニストを含有する製剤及び使用方法
CN109641044A (zh) 2016-05-30 2019-04-16 吉奥瓦科斯公司 用于产生对乙型肝炎病毒的免疫应答的组合物和方法
IL298227B1 (en) 2016-06-01 2024-05-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
WO2019012371A1 (en) 2017-07-11 2019-01-17 Pfizer Inc. IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT
EP4088783A1 (de) 2017-08-01 2022-11-16 Ab Studio Inc. Spezifische antikörper und verwendungen davon
MX2020005364A (es) 2017-11-24 2020-08-13 Eucure Beijing Biopharma Co Ltd Anticuerpos anti-ox40 y usos de los mismos.
CA3204873A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting muc16 and uses thereof
KR102637862B1 (ko) 2017-12-13 2024-02-19 이노비오 파마수티컬즈, 인크. 메소텔린을 표적으로 하는 암 백신 및 이의 용도
MX2020006216A (es) 2017-12-13 2020-08-31 Inovio Pharmaceuticals Inc Vacunas contra el cancer dirigidas a prame y sus usos.
CA3091352A1 (en) 2018-02-21 2019-08-29 The University Of Montana Diaryl trehalose compounds and uses thereof
JP7110369B2 (ja) 2018-02-23 2022-08-01 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド 抗ｐｄ－１抗体及びその用途
US11572381B2 (en) 2018-03-02 2023-02-07 The University Of Montana Immunogenic trehalose compounds and uses thereof
JP7212138B2 (ja) 2018-07-20 2023-01-24 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
CN112739718A (zh) 2018-09-12 2021-04-30 祐和医药科技(北京)有限公司 抗tnfrsf9抗体及其用途
KR20220089688A (ko) 2018-11-19 2022-06-28 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-pd-1 항체 및 이의 용도
KR20210133234A (ko) 2019-02-18 2021-11-05 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 인간화 면역글로불린 유전자좌를 갖는 유전적으로 변형된 비-인간 동물
EP3972636A4 (de) 2019-05-23 2023-08-02 The University Of Montana Impfstoffadjuvantien basierend auf tlr-rezeptor-liganden
IL298632A (en) 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Non-human animals genetically modified with a common light chain immunoglobulin locus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
US4728609A (en) * 1983-01-10 1988-03-01 Hoffmann-La-Roche Inc. Recombinant growth hormone releasing factor
US4562155A (en) * 1983-05-19 1985-12-31 The Wistar Institute Of Anatomy And Biology Hybrid viral plasmid and microorganisms containing same

Also Published As

Publication number Publication date
DE3685833D1 (de) 1992-08-06
DE3685833T2 (de) 1992-12-17
EP0198328B1 (de) 1992-07-01
GB8508845D0 (en) 1985-05-09
CA1316849C (en) 1993-04-27
US5017487A (en) 1991-05-21
AU595190B2 (en) 1990-03-29
EP0198328A2 (de) 1986-10-22
AU5539886A (en) 1986-10-09
JPS61289888A (ja) 1986-12-19
DK112586A (da) 1986-10-05
DK112586D0 (da) 1986-03-11
JPH07265085A (ja) 1995-10-17
EP0198328A3 (en) 1988-06-29

Similar Documents

Publication Publication Date Title
ZA862356B (en) Vaccinia dna
EP0232517A3 (en) Pipette
GB8618679D0 (en) Construction
GB8626914D0 (en) Dna clone
DE3664088D1 (en) Soil-tilling implement
GB8611955D0 (en) Volume-batching implement
GB8623207D0 (en) Soil-tilling implement
GB8529275D0 (en) Dna recombination
GB8605834D0 (en) Reagent
GB8506706D0 (en) Skid-sensing means
GB2189713B (en) Y
IE851261L (en) Dna sequence
GB8520191D0 (en) Dna sequence
GB8500336D0 (en) Dna recombinants
GB2177209B (en) Improved barograph
GB8524726D0 (en) Dna sequences
ZA869005B (en) Landboukundige implement
GB8515678D0 (en) Dna coding
GB8508265D0 (en) Dna coding
CS732186A1 (en) Zarizeni pro posuv pohybliveho dna zasobniku sazece brambor
GB8522439D0 (en) Reagent
BG40990A1 (en) Aphrodisiatic means
BG40669A1 (en) Herbicidic means
BG40591A1 (en) Hydroisolation means
BG39653A1 (en) Cytoquininic means